A. Barbeau
About
In The Last Decade
A. Barbeau
161 papers receiving 3.3k citations
Peers
Comparison fields: 5 of 126
- Cellular and Molecular Neuroscience 2.1k
- Molecular Biology 1.6k
- Neurology 981
- Cell Biology 496
- Physiology 383
Countries citing papers authored by A. Barbeau
This map shows the geographic impact of A. Barbeau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Barbeau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Barbeau more than expected).
Fields of papers citing papers by A. Barbeau
This network shows the impact of papers produced by A. Barbeau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Barbeau. The network helps show where A. Barbeau may publish in the future.
Co-authorship network of co-authors of A. Barbeau
This figure shows the co-authorship network connecting the top 25 collaborators of A. Barbeau. A scholar is included among the top collaborators of A. Barbeau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Barbeau. A. Barbeau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | Linkage studies of Friedreich ataxia by means of blood-group and protein markers | 2 |
| 3 | 4 | |
| 4 | 1 | |
| 5 | 8 | |
| 6 | Investigation of the relationship between some brain peptides and neurotransmitters. | 1 |
| 7 | 8 | |
| 8 | [Physiological trials with MIF-I in Parkinson's disease (author's transl)]. | 3 |
| 9 | 3 | |
| 10 | Recent developments in Parkinson's disease and Huntington's chorea. | 7 |
| 11 | Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease. | 42 |
| 12 | High-level levodopa therapy in Parkinson's disease: five years later. | 13 |
| 13 | 152 | |
| 14 | [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602]. | 3 |
| 15 | Adverse clinical side effects of levodopa therapy. | 41 |
| 16 | Biochimie et traitement de la maladie de Parkinson. | 1 |
| 17 | [L-dopa and Parkinson's disease]. | 2 |
| 18 | The "pink spot", 3,4-dimethoxyphenylethylamine and dopamine. Relationship to Parkinson's disease and to schizophrenia. | 10 |
| 19 | [HUNTINGTON'S CHOREA IN FRENCH CANADIANS. PRELIMINARY STUDY]. | 8 |
| 20 | Some biochemical aspects of extrapyramidal diseases. | 8 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.